ATE351924T1 - Bestimmung der empfindlichkeit zu autoimmunerkrankungen, ins besondere typ 1 diabetes - Google Patents

Bestimmung der empfindlichkeit zu autoimmunerkrankungen, ins besondere typ 1 diabetes

Info

Publication number
ATE351924T1
ATE351924T1 AT03022242T AT03022242T ATE351924T1 AT E351924 T1 ATE351924 T1 AT E351924T1 AT 03022242 T AT03022242 T AT 03022242T AT 03022242 T AT03022242 T AT 03022242T AT E351924 T1 ATE351924 T1 AT E351924T1
Authority
AT
Austria
Prior art keywords
diabetes
type
individual
risk
sensitivity
Prior art date
Application number
AT03022242T
Other languages
English (en)
Inventor
Daniel B Mirel
Henry A Erlich
Teodorica L Bugawan
Janelle A Noble
Ana Maria Valdez
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/267,844 external-priority patent/US7205106B1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE351924T1 publication Critical patent/ATE351924T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03022242T 2002-10-04 2003-10-01 Bestimmung der empfindlichkeit zu autoimmunerkrankungen, ins besondere typ 1 diabetes ATE351924T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26496502A 2002-10-04 2002-10-04
US10/267,844 US7205106B1 (en) 2001-07-20 2002-10-08 Association of polymorphisms in IL4-related genes with autoimmune disease

Publications (1)

Publication Number Publication Date
ATE351924T1 true ATE351924T1 (de) 2007-02-15

Family

ID=31996810

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03022242T ATE351924T1 (de) 2002-10-04 2003-10-01 Bestimmung der empfindlichkeit zu autoimmunerkrankungen, ins besondere typ 1 diabetes

Country Status (6)

Country Link
EP (1) EP1405921B1 (de)
JP (1) JP2004267200A (de)
AT (1) ATE351924T1 (de)
CA (1) CA2441701C (de)
DE (1) DE60311207T2 (de)
ES (1) ES2279916T3 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006051886A1 (ja) * 2004-11-12 2008-05-29 国立大学法人大阪大学 組織破壊によって機能障害を来たす自己免疫疾患の重症化の可能性を予測する方法
CA2724475C (en) * 2008-05-16 2019-05-07 The Children's Hospital Of Philadelphia Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023410A2 (en) * 1999-09-28 2001-04-05 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 13 gene
WO2001023404A1 (en) * 1999-09-30 2001-04-05 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin-4 gene

Also Published As

Publication number Publication date
JP2004267200A (ja) 2004-09-30
DE60311207D1 (de) 2007-03-08
CA2441701C (en) 2010-07-13
EP1405921B1 (de) 2007-01-17
EP1405921A1 (de) 2004-04-07
CA2441701A1 (en) 2004-04-04
ES2279916T3 (es) 2007-09-01
DE60311207T2 (de) 2007-12-06

Similar Documents

Publication Publication Date Title
CA2764693C (en) Risk markers for cardiovascular disease
WO2001057274A8 (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human heart
ES2186926T3 (es) Deteccion de la predisposicion genetica a la retinopatia diabetica amenazante de la vision.
RU2003123597A (ru) Белок, действующий в комплексе с рецептором андрогена
DE60007352D1 (de) Genetischer test zur bestimmung der nicht-wirksamkeit einer behandlung mit statinmedikamenten
EP2345744A3 (de) Nichtinvasives, pränatales in-vitro-verfahren zur detektion des normalen gesundheitszustandes, des zustandes eines gesunden trägers oder des zustandes eines mit mukoviszidose infizierten trägers
KR102346184B1 (ko) 피부 보습 위험도 예측용 바이오마커 및 이의 용도
ATE351924T1 (de) Bestimmung der empfindlichkeit zu autoimmunerkrankungen, ins besondere typ 1 diabetes
RU2003130071A (ru) Количественный диагностический анализ гипертензии
ATE415491T1 (de) Oligonucleotide zur markierung von oligonukleotidsonden und proteine
JP4295955B2 (ja) インターフェロンαレセプター２型遺伝子の多型およびその使用
JP2004528032A5 (de)
ES2319510T3 (es) Marcador polimorfico que puede ser utilizado para determinar la eficacia de la terapia con interferon.
WO2001081541A3 (en) Pcr-hybridization assays specific for integrated retroviruses
CN113881672B (zh) 乙型肝炎病毒感染者miRNA分子标志物组合及其应用
JPWO2003087360A1 (ja) 動脈硬化性疾患危険度判定方法、動脈硬化性疾患危険度測定方法、動脈硬化性疾患危険度判定用マイクロアレイ、動脈硬化性疾患危険度判定装置および動脈硬化性疾患危険度判定プログラム
JP3751867B2 (ja) インターフェロンを投与されるべき個体においてインターフェロン療法の有効性を予測する方法、その方法をコンピュータにより実行させるためのプログラム、インターフェロン感受性に関連する多型部位の遺伝子型を検出するための核酸プローブ、およびその核酸プローブを具備する塩基配列検出用チップ
CN113981141B (zh) 乙型肝炎感染患者和携带者血浆中的一组分子标志物及其用途
JP7101358B1 (ja) 肝臓疾患の発症リスクの検出方法、及び肝臓疾患の発症リスク検出用キット
KR102297562B1 (ko) 피부 유분 위험도 예측용 바이오마커 및 이의 용도
Xu et al. Polymorphisms in the genes for coagulation factor II, V, VII in patients undergoing coronary angiography
KR101881812B1 (ko) 운동 반응도 예측용 바이오마커
RU2004123610A (ru) Способ обнаружения предрасположенности к кардиоваскулярному заболеванию
ATE478147T1 (de) Aus einem neuroblastom isolierte nukleinsäuren
CN1455003A (zh) 一种sars冠状病毒荧光分子信标pcr检测技术

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1405921

Country of ref document: EP